GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmaxis Ltd (OTCPK:PXSLY) » Definitions » Operating Margin %

Pharmaxis (Pharmaxis) Operating Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Pharmaxis Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Pharmaxis's Operating Income for the six months ended in Dec. 2023 was $-5.69 Mil. Pharmaxis's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Pharmaxis's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Good Sign:

Syntara Ltd operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Pharmaxis's Operating Margin % or its related term are showing as below:

PXSLY' s Operating Margin % Range Over the Past 10 Years
Min: -1096.76   Med: -307.81   Max: 25.35
Current: -458.85


PXSLY's Operating Margin % is ranked worse than
93.12% of 1018 companies
in the Drug Manufacturers industry
Industry Median: 6.125 vs PXSLY: -458.85

Pharmaxis's 5-Year Average Operating Margin % Growth Rate was 0.60% per year.

Pharmaxis's Operating Income for the six months ended in Dec. 2023 was $-5.69 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-13.79 Mil.


Pharmaxis Operating Margin % Historical Data

The historical data trend for Pharmaxis's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaxis Operating Margin % Chart

Pharmaxis Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -455.99 -305.46 -309.01 -306.57 -438.67

Pharmaxis Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -173.83 -778.95 -1,032.41 -269.16 -

Competitive Comparison of Pharmaxis's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmaxis's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaxis's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmaxis's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Pharmaxis's Operating Margin % falls into.



Pharmaxis Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Pharmaxis's Operating Margin % for the fiscal year that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=-16.972 / 3.869
=-438.67 %

Pharmaxis's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-5.694 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaxis  (OTCPK:PXSLY) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Pharmaxis Operating Margin % Related Terms

Thank you for viewing the detailed overview of Pharmaxis's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaxis (Pharmaxis) Business Description

Traded in Other Exchanges
Address
20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.

Pharmaxis (Pharmaxis) Headlines